Patent: 9,920,033
✉ Email this page to a colleague
Summary for Patent: 9,920,033
Title: | Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof |
Abstract: | The present invention relates to a crystalline form of N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,- 5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide p-toluenesulfonate, the process for preparing the crystalline form thereof, and the pharmaceutical compositions comprising the crystalline form thereof. This invention also relates to a method of using such a crystalline form and pharmaceutical compositions comprising the crystalline form thereof in the treatment of hyperproliferative diseases in mammals, especially in humans. |
Inventor(s): | Xi; Ning (Newbury Park, CA), Sun; Mingming (Guangdong, CN) |
Assignee: | Calitor Sciences, LLC (Newbury Park, CA) Sunshine Lake Pharma Co., LTD. (Dongguan, Guangdong, CN) |
Application Number: | 15/350,013 |
Patent Claims: | see list of patent claims |
Details for Patent 9,920,033
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2035-11-14 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2035-11-14 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2035-11-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |